Merck and Ridgeback’s Molnupiravir medicine demonstrates activity against Omicron variant

Jan 29, 2022, at 03:49 pm

New Jersey: Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics has announced data from six preclinical studies demonstrating that molnupiravir, an investigational oral antiviral COVID-19 medicine, was active against the SARS-CoV-2 variant Omicron (B1.1.529) in vitro.

Anti-COVID-19 pill Molnupiravir cleared by DCGI has safety concerns: ICMR chief

Jan 07, 2022, at 04:36 pm

New Delhi/IBNS: Indian Council of Medical Research (ICMR) chief Balram Bhargava on Wednesday said anti-COVID-19 pill Molnupiravir, which has been cleared by India's drug regulator, has "major safety concerns".

Merck's Covid pill Molnupiravir out of national treatment protocol for 'major safety concerns': ICMR

Jan 06, 2022, at 04:36 am

New Delhi/IBNS: Indian Council for Medical Research (ICMR) has cited 'major safety concerns' for not adding Merck's coronavirus pill, Molnupiravir, to the national treatment protocol.

Indian drugs regulator seeks more info on Merck's Covid-19 pill

Nov 19, 2021, at 10:15 pm

New Delhi/IBNS: Indian drug regulator CDSCO's expert panel has sought additional data from the companies seeking emergency use authorisation (EUA) for MSD's Covid-19 antiviral medication molnupiravir, media reports said.

UK becomes first country to approve Merck's Covid-19 pill molnupiravir: Report

Nov 05, 2021, at 02:34 am

London/IBNS: Britain on Thursday became the first country to approve COVID-19 antiviral pill jointly developed by U.S.-based Merck and Ridgeback Biotherapeutics, media reports said.